Table 4.

AZD1446 differences to placebo on efficacy measures at week 2 (cognitive measures, intent-to-treat population)

Score	Treatment	Nicotine non-users					Treatment	Nicotine users
		Number	LS mean	Difference to placebo				Number	LS mean	Difference to placebo
				LS mean	95 % CI	P value				LS mean	95 % CI	P value
International	Placebo	41	8.9				Placebo	17	45.8
Shopping List	80 mg tid	26	9.6	0.71	−0.27, 1.68	0.22	80 mg tid	17	41.4	−0.08	−1.15, 0.98	0.98
Task-recall	80 mg qd	25	9.6	0.71	−0.28, 1.70	0.22	80 mg qid	19	42.8	0.36	−0.67, 1.40	0.65
	10 mg tid	26	9.2	0.34	−0.65, 1.33	0.77
International	Placebo	41	26.9				Placebo	17	9.5
Shopping List	80 mg tid	26	28.3	1.37	−0.11, 2.86	0.08	80 mg tid	17	9.5	0.91	−1.07, 2.89	0.48
Task-acquisition	80 mg qd	25	28.4	1.50	−0.02, 3.02	0.06	80 mg qid	19	9.9	1.29	−0.66, 3.24	0.24
	10 mg tid	26	27.3	0.41	−1.10, 1.93	0.87
One Back	Placebo	41	1.2				Placebo	17	26.6
Memory Task	80 mg tid	26	1.2	−0.04	−0.12, 0.04	0.61	80 mg tid	17	27.5	−0.04	−0.18, 0.10	0.73
	80 mg qd	25	1.3	0.03	−0.05, 0.11	0.71	80 mg qid	19	27.9	−0.01	−0.15, 0.13	0.99
	10 mg tid	26	1.3	0.04	−0.04, 0.12	0.46
Two Back Memory Task	Placebo	41	1.2				Placebo	17	1.3
	80 mg tid	26	1.2	−0.04	−0.13, 0.06	0.69	80 mg tid	17	1.2	0.03	−0.08, 0.13	0.80
	80 mg qd	25	1.2	−0.04	−0.13, 0.06	0.70	80 mg qid	19	1.3	0.04	−0.07, 0.15	0.58
	10 mg tid	26	1.3	0.04	−0.05, 0.14	0.59
Groton Maze Learning Task	Placebo	41	39.8				Placebo	17	1.2
	80 mg tid	26	37.3	−2.56	−7.87, 2.75	0.55	80 mg tid	17	1.2	−4.42	−11.64, 2.80	0.29
	80 mg qd	25	33.7	−6.13	−11.47, −.79	0.02a	80 mg qid	19	1.2	−3.03	−9.92, 3.87	0.51
	10 mg tid	26	39.1	−0.75	−6.11, 4.61	0.98

For the International Shopping List (both), One Back Memory and Two Back Memory tasks, improved performance is indicated by positive numerical change. For the Stop Signal and Groton Maze Learning tasks, improved performance is indicated by negative numerical change. Results are corrected for multiple comparisons between treatment groups

^aStatistically significant changes